Drug executive says regulatory obstacles delay new drugs, increase costs

07/16/2013 | BioSpectrum Asia

The actions of government regulatory agencies have contributed to declines in research productivity, discouraged investment and raised costs for the pharmaceutical industry throughout the world, according to Tony Alvarez, president of MSD KK in Japan, speaking at the in-Pharma Japan and Interphex Japan meetings in Tokyo. He alleged that such agencies, including the U.S. FDA, are deliberately blocking drug research and commercialization as a means of controlling costs.

View Full Article in:

BioSpectrum Asia

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC